Iniparib

Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

Product Specifications

CAS Number

[160003-66-7]

Product Name Alternative

BSI-201; NSC-746045; IND-71677

UNSPSC

12352005

Hazard Statement

H302, H319

Target

Influenza Virus; PARP

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BSI-201.html

Purity

99.74

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(C([N+]([O-])=O)=C1)I)N

Molecular Formula

C7H5IN2O3

Molecular Weight

292.03

Precautions

H302, H319

References & Citations

[1]Liu X, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18 (2) :510-23.|[2]Yin S, et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One. 2017 Aug 17;12 (8) :e0183578.|[3]Ma W, et al. Differential effects of poly (ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A. 2012 Apr 24;109 (17) :6590-5.